Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Aeglea BioTherapeutics

Nasdaq:AGLE
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGLE
Nasdaq
$137M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • Aeglea BioTherapeutics has significant price volatility in the past 3 months.
AGLE Share Price and Events
7 Day Returns
18.3%
NasdaqGM:AGLE
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-41.4%
NasdaqGM:AGLE
0%
US Biotechs
-11.5%
US Market
AGLE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aeglea BioTherapeutics (AGLE) 18.3% -31.2% -40.3% -41.4% -36.6% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • AGLE underperformed the Biotechs industry which returned 0% over the past year.
  • AGLE underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
AGLE
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aeglea BioTherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aeglea BioTherapeutics. This is due to cash flow or dividend data being unavailable. The share price is $4.72.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aeglea BioTherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aeglea BioTherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AGLE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.45
NasdaqGM:AGLE Share Price ** NasdaqGM (2020-03-27) in USD $4.72
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aeglea BioTherapeutics.

NasdaqGM:AGLE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AGLE Share Price ÷ EPS (both in USD)

= 4.72 ÷ -2.45

-1.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aeglea BioTherapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Aeglea BioTherapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aeglea BioTherapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:AGLE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
15.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aeglea BioTherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aeglea BioTherapeutics's assets?
Raw Data
NasdaqGM:AGLE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.07
NasdaqGM:AGLE Share Price * NasdaqGM (2020-03-27) in USD $4.72
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:AGLE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AGLE Share Price ÷ Book Value per Share (both in USD)

= 4.72 ÷ 2.07

2.28x

* Primary Listing of Aeglea BioTherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aeglea BioTherapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Aeglea BioTherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aeglea BioTherapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aeglea BioTherapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aeglea BioTherapeutics expected to grow at an attractive rate?
  • Unable to compare Aeglea BioTherapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aeglea BioTherapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Aeglea BioTherapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AGLE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AGLE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 15.1%
NasdaqGM:AGLE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 64.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AGLE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AGLE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 116 -54 -11 3
2023-12-31 69 -83 -49 3
2022-12-31 41 -75 -80 4
2021-12-31 2 -86 -95 6
2020-12-31 0 -83 -86 6
2020-03-28
NasdaqGM:AGLE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -66 -78
2019-09-30 0 -57 -72
2019-06-30 0 -48 -62
2019-03-31 2 -41 -53
2018-12-31 4 -32 -44
2018-09-30 5 -31 -36
2018-06-30 7 -30 -32
2018-03-31 6 -27 -29
2017-12-31 5 -25 -27
2017-09-30 5 -23 -26
2017-06-30 5 -22 -25
2017-03-31 5 -20 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aeglea BioTherapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Aeglea BioTherapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AGLE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Aeglea BioTherapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AGLE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.24 0.95 -1.43 2.00
2023-12-31 -1.08 -0.02 -2.13 2.00
2022-12-31 -1.64 -0.56 -2.46 4.00
2021-12-31 -2.45 -1.98 -2.98 6.00
2020-12-31 -2.51 -2.10 -2.96 6.00
2020-03-28
NasdaqGM:AGLE Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.45
2019-09-30 -2.41
2019-06-30 -2.30
2019-03-31 -2.23
2018-12-31 -2.13
2018-09-30 -1.89
2018-06-30 -1.81
2018-03-31 -1.82
2017-12-31 -1.80
2017-09-30 -1.83
2017-06-30 -1.81
2017-03-31 -1.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aeglea BioTherapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Aeglea BioTherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aeglea BioTherapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aeglea BioTherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aeglea BioTherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aeglea BioTherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aeglea BioTherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aeglea BioTherapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aeglea BioTherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aeglea BioTherapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AGLE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -78.25 15.73
2019-09-30 0.00 -71.66 14.90
2019-06-30 0.00 -62.00 13.91
2019-03-31 2.38 -53.40 13.02
2018-12-31 3.89 -44.35 12.63
2018-09-30 5.37 -35.93 11.44
2018-06-30 6.63 -31.89 11.15
2018-03-31 5.73 -29.11 10.59
2017-12-31 5.21 -27.24 10.07
2017-09-30 4.97 -26.24 9.80
2017-06-30 4.86 -24.60 8.84
2017-03-31 4.75 -23.40 8.93
2016-12-31 4.63 -21.70 8.39
2016-09-30 4.97 -20.20 7.96
2016-06-30 4.89 -17.38 7.25
2016-03-31 6.94 -13.37 6.93
2015-12-31 6.09 -11.52 5.95
2015-09-30 4.50 -10.72 4.96 -0.17
2015-06-30 3.43 -10.55 4.25 -0.10
2015-03-31 -11.52 2.60 -0.53
2014-12-31 -10.35 2.07
2013-12-31 -23.24 8.82 13.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aeglea BioTherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aeglea BioTherapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aeglea BioTherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aeglea BioTherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aeglea BioTherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aeglea BioTherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aeglea BioTherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aeglea BioTherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aeglea BioTherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aeglea BioTherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aeglea BioTherapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aeglea BioTherapeutics Company Filings, last reported 2 months ago.

NasdaqGM:AGLE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 60.08 0.00 71.95
2019-09-30 79.80 0.00 88.70
2019-06-30 99.62 0.00 105.54
2019-03-31 116.29 0.00 123.72
2018-12-31 67.43 0.00 74.51
2018-09-30 63.68 0.00 64.74
2018-06-30 73.45 0.00 72.19
2018-03-31 43.92 0.00 43.48
2017-12-31 50.34 0.00 50.30
2017-09-30 55.51 0.00 55.75
2017-06-30 62.60 0.00 63.39
2017-03-31 57.18 0.00 57.87
2016-12-31 62.97 0.00 63.50
2016-09-30 68.20 0.00 68.04
2016-06-30 73.92 0.00 73.58
2016-03-31 31.70 0.00 28.99
2015-12-31 36.10 0.00 33.06
2015-09-30 39.65 0.00 34.14
2015-06-30 42.90 0.00 39.08
2015-03-31 43.12 0.00 43.79
2014-12-31 1.87 0.00 2.62
2013-12-31 3.19 0.00 4.60
  • Aeglea BioTherapeutics has no debt.
  • Aeglea BioTherapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aeglea BioTherapeutics has sufficient cash runway for 1.1 years based on current free cash flow.
  • Aeglea BioTherapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 36.5% each year.
X
Financial health checks
We assess Aeglea BioTherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aeglea BioTherapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aeglea BioTherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aeglea BioTherapeutics dividends.
If you bought $2,000 of Aeglea BioTherapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aeglea BioTherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aeglea BioTherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AGLE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AGLE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aeglea BioTherapeutics has not reported any payouts.
  • Unable to verify if Aeglea BioTherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aeglea BioTherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aeglea BioTherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aeglea BioTherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aeglea BioTherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aeglea BioTherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aeglea BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anthony Quinn
COMPENSATION $3,842,134
AGE 57
TENURE AS CEO 2.7 years
CEO Bio

Dr. Anthony G. Quinn, M.B Ch.B., Ph.D., FRCP, has been President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. since July 19, 2018 and its Director since 2016. Dr. Quinn has served as a Director of Kaleido BioSciences, Inc. since February 2016. Dr. Quinn served as Interim Chief Executive Officer of Aeglea BioTherapeutics since July 2017 until July 19, 2018. Dr. Quinn is a Director of Generation Bio Co. Dr. Quinn served as Interim Chief Medical Officer of Aeglea Biotherapeutics, Inc. from April 21, 2017 to July 10, 2017. Dr. Quinn served as the Chief Medical Officer of Synageva BioPharma Corp. since August 2009 until June 2015 and served as its Executive Vice President from January 2014 to June 2015. Dr. Quinn served as the Senior Vice President and Head of Research & Development at Synageva BioPharma Corp. since August 2009 until January 2014. Dr. Quinn joined Synageva from Roche Palo Alto, LLC where, from September 2004 until joining Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation Disease Biology. Since October 2015 until July 2017, Dr. Quinn has worked as a private consultant for IDBioPharm Consulting LLC. While at Roche, Dr. Quinn managed programs in rheumatology and respiratory indications in exploratory development and biomarker and translational medicine activities in the late clinical and registration phase for MabThera™/Rituxan™, Actemra™ and Ocrelizumab. He joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capabilities at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche, he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK and he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has been a Director of Aeglea Biotherapeutics, Inc. since March 15, 2016. Dr. Quinn worked for Alexion Pharmaceuticals from June 2015 to September 2015. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science(B.MSc ) in General Pathology with First class honors and his M.B Ch.B (M.D.) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his Ph.D. degree in Cancer Research there. He completed a postdoctoral fellowship at University of California, San Francisco and is a fellow of the Royal College of Physicians London.

CEO Compensation
  • Anthony's compensation has increased whilst company is loss making.
  • Anthony's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Aeglea BioTherapeutics management team in years:

2.7
Average Tenure
51
Average Age
  • The tenure for the Aeglea BioTherapeutics management team is about average.
Management Team

Anthony Quinn

TITLE
President
COMPENSATION
$4M
AGE
57
TENURE
2.7 yrs

Charles York

TITLE
CFO & VP
COMPENSATION
$961K
AGE
42
TENURE
4.5 yrs

Leslie Sloan

TITLE
Chief Operating Officer
AGE
48
TENURE
2.6 yrs

Eugene Sackett

TITLE
Vice President of Human Resources

Ravi Rao

TITLE
Chief Medical Officer
TENURE
0.3 yrs

Michael Hanley

TITLE
Chief Commercial Officer
TENURE
0.3 yrs

Scott Rowlinson

TITLE
Vice President of Research
COMPENSATION
$608K
AGE
51
TENURE
6.1 yrs

F. Dorr

TITLE
Executive Officer
AGE
66
TENURE
2.9 yrs
Board of Directors Tenure

Average tenure and age of the Aeglea BioTherapeutics board of directors in years:

3.5
Average Tenure
56
Average Age
  • The tenure for the Aeglea BioTherapeutics board of directors is about average.
Board of Directors

Russ Cox

TITLE
Independent Chairman of the Board
COMPENSATION
$179K
AGE
56
TENURE
1.2 yrs

Anthony Quinn

TITLE
President
COMPENSATION
$4M
AGE
57
TENURE
4 yrs

Sandy Mahatme

TITLE
Independent Director
COMPENSATION
$188K
AGE
54
TENURE
4.8 yrs

Sue Bruhn

TITLE
Independent Director
COMPENSATION
$181K
AGE
56
TENURE
3.1 yrs

Armen Shanafelt

TITLE
Independent Director
COMPENSATION
$211K
AGE
60
TENURE
6.3 yrs

Keith Flaherty

TITLE
Member of Scientific Advisory Board
AGE
48
TENURE
3.5 yrs

Arthur Frankel

TITLE
Member of Scientific Advisory Board
TENURE
3.5 yrs

Wayne Klohs

TITLE
Member of Scientific Advisory Board
TENURE
3.5 yrs

Matthew Vander Heiden

TITLE
Member of Scientific Advisory Board
TENURE
3.5 yrs

Dan Von Hoff

TITLE
Member of Scientific Advisory Board
AGE
71
TENURE
3.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Jun 19 Buy Anthony Quinn Individual 12. Jun 19 14. Jun 19 31,905 $6.23 $196,453
22. May 19 Buy Anthony Quinn Individual 20. May 19 22. May 19 26,592 $6.89 $180,032
17. May 19 Buy Anthony Quinn Individual 15. May 19 17. May 19 17,994 $6.83 $121,295
X
Management checks
We assess Aeglea BioTherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aeglea BioTherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Aeglea BioTherapeutics (NASDAQ:AGLE) Share Price Has Gained 50% And Shareholders Are Hoping For More

It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at. … There are plenty of other companies that have insiders buying up shares. … You probably do not want to miss this free list of growing companies that insiders are buying.

Simply Wall St -

Aeglea BioTherapeutics (NASDAQ:AGLE) Seems To Be Really Weighed Down By Its Debt

NasdaqGM:AGLE Historical Debt, July 17th 2019 A Look At Aeglea BioTherapeutics's Liabilities Zooming in on the latest balance sheet data, we can see that Aeglea BioTherapeutics had liabilities of US$11.8m due within 12 months and liabilities of US$424.0k due beyond that. … Aeglea BioTherapeutics boasts net cash, so it's fair to say it does not have a heavy debt load! … Even though its balance sheet seems sufficiently liquid, debt always makes us a little nervous if a company doesn't produce free cash flow regularly.

Simply Wall St -

How Does Investing In Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Impact The Volatility Of Your Portfolio?

In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price. … If the future looks like the past, we could therefore consider it likely that the stock price will experience share price volatility that is roughly similar to the overall market. … What this means for you: It is probable that there is a link between the share price of Aeglea BioTherapeutics and the broader market, since it has a beta value quite close to one.

Simply Wall St -

What Kind Of Investor Owns Most Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)?

View our latest analysis for Aeglea BioTherapeutics NasdaqGM:AGLE Ownership Summary, May 23rd 2019 What Does The Institutional Ownership Tell Us About Aeglea BioTherapeutics? … Insider Ownership Of Aeglea BioTherapeutics The definition of company insiders can be subjective, and does vary between jurisdictions. … Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company.

Simply Wall St -

Need To Know: Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Have Been Selling Shares

But logic dictates you should pay some attention to whether insiders are buying or selling shares. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price.

Simply Wall St -

If You Had Bought Aeglea BioTherapeutics Stock A Year Ago, You Could Pocket A 29% Gain Today

Aeglea BioTherapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last year Aeglea BioTherapeutics saw its revenue grow by 8.0%. … In keeping with the revenue growth, the share price gained 29% in that time.

Simply Wall St -

Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price?

In finance, Beta is a measure of volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Who Has Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Aeglea BioTherapeutics, Inc. … The Last 12 Months Of Insider Transactions At Aeglea BioTherapeutics. … Aaron Schuchart was the only individual insider to sell shares in the last twelve months

Simply Wall St -

How Many Aeglea BioTherapeutics Inc (NASDAQ:AGLE) Shares Do Institutions Own?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Aeglea BioTherapeutics is a smaller company with a market capitalization of US$189m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Aeglea BioTherapeutics Inc (NASDAQ:AGLE) Is Expected To Breakeven

Aeglea BioTherapeutics Inc's (NASDAQ:AGLE):. … Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. … The US$234.33m market-cap posted a loss in its most recent financial year of -US$27.24m and a latest trailing-twelve-month loss of -US$29.11m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Company Info

Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company’s lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Details
Name: Aeglea BioTherapeutics, Inc.
AGLE
Exchange: NasdaqGM
Founded: 2013
$137,282,318
29,085,237
Website: http://www.aegleabio.com
Address: Aeglea BioTherapeutics, Inc.
805 Las Cimas Parkway,
Suite 100,
Austin,
Texas, 78746,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AGLE Common Stock Nasdaq Global Market US USD 08. Apr 2016
Number of employees
Current staff
Staff numbers
76
Aeglea BioTherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:11
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/02/27
Last earnings filing: 2020/02/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.